Prostatic adenocarcinoma metastatic to the head and neck and the workup of an unknown epithelioid neoplasm

Head and Neck

Volumn 26, Issue 2, 2004, Pages 171-178

  Hunt, Jennifer L ^a   Tomaszewski, John E ^b   Montone, Kathleen T ^c  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^c ABINGTON MEMORIAL HOSPITAL   (United States)

Author keywords

Head and neck; Prostate carcinoma; Unknown primary

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; HORMONE; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL GROWTH; CELL ULTRASTRUCTURE; CLINICAL ARTICLE; CLINICAL FEATURE; DATA BASE; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; EPITHELIOID CELL; FOLLOW UP; HEAD AND NECK CANCER; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MEDICAL RECORD; METASTASIS; NUCLEOLUS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; SURVIVAL TIME; TUMOR BIOPSY; UNITED STATES;

ADENOCARCINOMA; AGED; CARCINOMA; COMBINED MODALITY THERAPY; DIAGNOSIS, DIFFERENTIAL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, UNKNOWN PRIMARY; PROGNOSIS; PROSTATIC NEOPLASMS; SURVIVAL RATE;

EID: 0742323417     PISSN: 10433074     EISSN: None     Source Type: Journal    
DOI: 10.1002/hed.10353     Document Type: Article

References (32)

1. Catalona WJ, Smith DS, Ratliff TL, et al. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993;270:948-954.
2. Gleason DF, Tennenbaum M. The prostate Philadelphia: Lee and Febiger; 1977.
3. Landers SH, Taylor M, Bolden S, et al. Cancer statistics 1998. Cancer 1998;48:8-29.
4. Gupta A, Baidas S, Cumberlin RK. Brain stem metastasis as the only site of spread in prostate carcinoma. Cancer 1994;74:2516-2519.
5. Kasabian NG, Previte SR, Kaloustian HD, et al. Adenocarcinoma of the prostate presenting initially as an intracerebral tumor. Cancer 1992;70:2149-2151.
6. Lynes WL, Bostick DG, Freiha FS, et al. Parenchymal brain metastases from adenocarcinoma of the prostate. Urology 1986;28:280-287.
7. Bland LI, Welch WC, Okawara SH. Large cystic intraparenchymal brain metastasis from prostate cancer. Neuroradiology 1992;34:70-72.
8. Chung TS, Thannikkary C. Carcinoma of the prostate with brain metastasis. J Surg Oncol 1986;33:103-105.
9. Penley MW, Kim YC, Pribram HFW. Subdural metastases from prostatic adenocarcinoma. Surg Neurol 1981;16:131-134.
10. Leibman BD, Dillioglugil O, Wheeler TM, et al. Distant metastasis after radical prostatectomy in patients without an elevated serum prostate specific antigen level. Cancer 1995;76:2530-2534.
11. Rao GK. Carcinoma of the prostate presenting as intracranial tumor with multiple cranial nerve palsies. Urology 1982;19:433-435.
12. Sarma DP, Godeau L. Brain metastasis from prostatic cancer. J Surg Oncol 1983;23:173-174.
13. Castaldo JE, Bernt JL, Meier FA, et al. Intracranial metastases due to prostatic carcinoma. Cancer 1983;52:1739-1747.
14. McMenamin PG, Anderson JD, Baker JJ. Prostatic carcinoma presenting in neck metastasis. J Otolaryngol 1989;3:119-124.
15. Jones H, Anthony PP. Metastatic prostatic carcinoma presenting as left-sided cervical lymphadenopathy: a series of 11 cases. Histopathology 1992;21:149-154.
16. Kirkali Z, Koyuncuoglu M, Pabuccuoglu U, et al. Prostatic carcinoma presenting with painless parotid mass. Urology 1995;36:406-407.
17. Simpson RH, Skalova A. Metastatic carcinoma of the prostate presenting as parotid tumour. Histopathology 1997;30:70-74.
18. LiVolsi VA. Prostatic carcinoma presenting as a primary parotid tumor. Oral Surg Oral Med Oral Pathol 1979;48:447-450.
19. Couldwell WT, Chandrasoma PT, Weiss MH. Pituitary gland metastasis from adenocarcinoma of the prostate. Case report. J Neurosurg 1989;71:138-140.
20. Kattah JC, Chrousos GC, Roberts J, et al. Metastatic prostate cancer to the optic canal. Ophthalmology 1993;100:1711-1715.
21. Azana JM, de Misa RF, Gomez MI, et al. Cutaneous metastases from prostatic cancer. J Dermatol 1993;20:786-788.
22. Fan CY, Wang J, Barnes EL. Expression of androgen receptor and prostatic specific markers in salivary duct carcinoma: an immunohistochemical analysis of 13 cases and review of the literature. Am J Surg Pathol 2000;24:579-586.
23. Alanen KA, Kuopio T, Koskinen PJ, et al. Immunohistochemical labeling for prostate specific antigen in nonprostatic tissues. Pathol Res Prac 1999;192:233-237.
24. Lagendijk JH, Mullink H, Van Diest PJ, et al. Tracing the origin of adenocarcinomas with unknown primary using immunohistochemistry: differential diagnosis between colonic and ovarian carcinomas as primary sites. Hum Pathol 1998;29:491-497.
25. DeYoung BR, Wick MR. Immunohistologic evaluation of metastatic carcinomas of unknown origin: an algorithmic approach. Semin Diagn Pathol 2000;17:184-193.
26. Diamandis EP, Yu H. Nonprostatic sources of prostate-specific antigen. Urol Clin North Am 1997;24:275-282.
27. Elgamal AA, Ectors NL, Sunardhi-Widyaputra S, et al. Detection of prostate specific antigen in pancreas and salivary glands: a potential impact on prostate cancer overestimation. J Urol 1996;156:464-468.
28. Chu P, Wu E, Weiss LM. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod Pathol 2000;13:962-972.
29. Oliveira AM, Tazelaar HD, Myers JL, et al. Thyroid transcription factor-1 distinguishes metastatic pulmonary from well-differentiated neuroendocrine tumors of other sites. American J Surg Pathol 2001;25:815-819.
30. Orchard GE. Comparison of immunohistochemical labeling of melanocyte differentiation antibodies melan-A, tyrosinase and HMB 45 with NKIC3 and S100 protein in the evaluation of benign naevi and malignant melanoma. Histochem J 2000;32:475-481.
31. Busam KJ, Iversen K, Berwick M, et al. Immunoreactivity with the anti-MAGE antibody 57B in malignant melanoma: frequency of expression and correlation with prognostic parameters. Mod Pathol 2000;13:459-465.
32. Bejarano PA, Nikiforov YE, Swenson ES, et al. Thyroid transcription factor-1, thyroglobulin, cytokeratin 7, and cytokeratin 20 in thyroid neoplasms. Appl Immunohistochem Mol Morphol 2000;8:189-194.